US 12,145,963 B2
Phenothiazine derivatives and uses thereof
David A. Bumcrot, Belmont, MA (US); Alfica Sehgal, Belmont, MA (US); and Donald L. Hertzog, Cambridge, MA (US)
Assigned to Camp4 Therapeutics Corporation, Cambridge, MA (US)
Filed by Camp4 Therapeutics Corporation, Cambridge, MA (US)
Filed on Nov. 16, 2022, as Appl. No. 18/056,008.
Application 18/056,008 is a continuation of application No. 16/640,482, granted, now 11,542,290, previously published as PCT/US2019/026158, filed on Apr. 5, 2019.
Claims priority of provisional application 62/653,741, filed on Apr. 6, 2018.
Claims priority of provisional application 62/653,752, filed on Apr. 6, 2018.
Prior Publication US 2023/0257410 A1, Aug. 17, 2023
Int. Cl. C07D 417/06 (2006.01); C07D 279/28 (2006.01); C07H 7/06 (2006.01)
CPC C07H 7/06 (2013.01) [C07D 279/28 (2013.01); C07D 417/06 (2013.01)] 1 Claim
OG exemplary drawing
 
1. A compound of formula (II):

OG Complex Work Unit Chemistry
or a pharmaceutically acceptable salt thereof, wherein
R1 is selected from the group consisting of hydrogen, —OH, and C1-6alkoxy;
R2 is C1-6alkyl substituted with one or more substituents each independently selected from the group consisting of —OH, C1-6alkoxy, —C(O)NRaRb, —C(O)Rc, —C(O)ORd, S(O)2C1-6alkyl, and S(O)2NRaRb;
R3 is hydrogen or C1-6alkyl;
Ra, Rb, Rc, and Rd are each independently hydrogen or C1-6alkyl;
n is 1 or 2; and
m is selected from the group consisting of 1, 2, or 3.